scholarly journals The Prognostic and Clinicopathological Significance of LASP1 Expression in Cancer Patients: Systematic Review and Meta-Analysis

2021 ◽  
Author(s):  
Jian Luo ◽  
Yuanzhi Zhu ◽  
Ying Long ◽  
Fei Huang ◽  
Xiaozou Luo ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Lung Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Cancer Patients ◽  
Distant Metastasis ◽  
Meta Analysis ◽  
Tnm Stage ◽  
Node Metastasis ◽  
T Classification

Abstract Background Many cancer researchers have investigated the prognostic significance of LASP1 for survival of patients with various types of cancer. Nevertheless, the role LASP1 palyed in cancer prognosis remains unknown. In consequence, we carried out this study in order to comprehensively analyze the prognostic value of LASP1 in cancer patients. Methods A systematical research was conducted in electronic databases, such as PubMed, Embase and Web of Science. Eighteen studies meeting the inclusion criteria were enrolled. Overall survival (OS), recurrence-free survival (RFS) and various clinicopathological parameters were used as the endpoints in this study. Results A total of 2023 cancer patients from eighteen studies were finally enrolled into our meta-analysis. The results revealed that the cancer patients with high expression of LASP1 exhibited shorter OS (HR = 2.04, 95%CI = 1.77–2.34, P < 0.01) and RFS (HR = 2.11, 95%CI = 1.51–2.95, P < 0.01) than those with low expression of LASP1, and patients whose tumors expressed high LASP1 had shorter OS in lung cancer (HR = 2.20, 95%CI = 1.45–3.36, P < 0.01) and gastric cancer (HR = 1.64, 95%CI = 1.14–2.36, P < 0.01) respectively. Furthermore, the cancer patients whose tumors expressed high LASP1 were apparently associated with advanced TNM stage (OR = 2.92, 2.27–3.76, P < 0.01), earlier lymph node metastasis (OR = 2.69, 1.62–4.45, P < 0.01), advanced T classification (OR = 2.17, 1.48–3.18, P < 0.01) and earlier distant metastasis (OR = 2.56, 1.03–6.35, P = 0.04) when compared to those whose tumors expressed low LASP1. Conclusions Our study showed that the high LASP1 expression might be an undesirable predictor for patients with various types of cancers in the aspect of OS, RFS, TNM stage, lymph node metastasis, T classification and distant metastasis, and the high LASP1 expression might be an undesirable predictor for lung cancer patients and gastric cancer patients. Therefore, the expression of LASP1 might be utilized as a novel indicator in judging the prognosis of cancer patients, especially in lung cancer and gastric cancer.

scholarly journals Prognosis assessment of CD44+/CD24- in Breast Cancer Patients: a systematic review and meta-analysis

2021 ◽  
Author(s):  
Jingjing Gu ◽  
Dandan Chen ◽  
Zhiqiang li ◽  
Yongliang Yang ◽  
Zhaoming Ma ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Cancer Patients ◽  
Distant Metastasis ◽  
Tumor Size ◽  
Meta Analysis ◽  
Breast Cancer Patients ◽  
Clinical Prognosis ◽  
Node Metastasis

Abstract Purpose: This meta-analysis investigated the relationships between the CD44+/CD24- phenotype and tumor size, lymph node metastasis, distant metastasis, disease-free survival (DFS), and overall survival (OS) in 8036 postoperative breast cancer patients enrolled in 23 studies.Methods: A literature search of PubMed, Medline, Cochrane, Embase, and PMC was conducted to identify eligible studies. The combined odds ratios (ORs) and 95% confidence intervals (95%CIs) were analyzed to evaluate the relationships between the CD44+/CD24- phenotype and the pathological and biological characteristics of breast cancer patients, and the combined hazard ratios (HRs) and 95% CIs were calculated to evaluate the relationships between CD44+/CD24- and DFS and OS of breast cancer petients using Stata12.0 software.Results: The CD44+/CD24- phenotype were not related to the tumor size (tumor size > 2.0 cm vs ≤ 2.0 cm, combined OR = 0.98, 95%CI: 0.68–1.34, p = 0.792) and didn’t promote lymph node metastasis (lymph node metastasis vs. no lymph node metastasis, combined OR = 0.94, 95% CI: 0.71–1.26, p = 0.692) and distant metastasis (distant metastasis vs no distant metastasis, combined OR = 3.88, 95% CI: 0.93–16.24, p = 0.064). The CD44+/CD24- phenotype was negatively correlated with postoperative DFS (HR = 1.67, 95% CI: 1.35–2.07, p <0.00001) and OS (combined HR = 1.52, 95%CI: 1.21–1.91, p = 0.0004).Conclusion: These results suggested expression of the CD44+/CD24- phenotype can be used as a reliable indicator of clinical prognosis and a potential therapeutic targets in breastcancer patients.

scholarly journals The Correlation between miRNA and Lymph Node Metastasis in Gastric Cancer

2015 ◽  
Vol 2015 ◽  
pp. 1-7 ◽  
Author(s):  
Kuo-Hung Huang ◽  
Yuan-Tzu Lan ◽  
Wen-Liang Fang ◽  
Jen-Hao Chen ◽  
Su-Shun Lo ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Cancer Patients ◽  
Lymphovascular Invasion ◽  
Tnm Stage ◽  
Stromal Reaction ◽  
Node Metastasis ◽  
Gastric Cancer Patients ◽  
T Category

Lymph node metastasis (LNM) in gastric cancer is associated with higher rate of cancer recurrence and poor prognosis. As a result, a reliable biomarker for the prediction of LNM is important and would be valuable in the clinical practice. MiRNA microarray revealed that ten miRNAs were expressed significantly different among patients with or without LNM. A total of 46 gastric cancer patients were enrolled and divided into two groups (23 in each group) according to the presence or absence of LNM. RT-PCR of these 10 miRNAs was investigated and compared between the two groups. MiR-1207-5p was significantly upregulated in gastric cancer patients without LNM compared with those with LNM. Patients with upregulated miR-1207-5p had less scirrhous stromal reaction, less lymphovascular invasion, and earlier pathological T category, N category, and TNM stage, compared with those with downregulated or unchanged miR-1207-5p. Multivariate analysis showed that stromal reaction type, lymphovascular invasion, pathological T category and TNM stage, and expression of miR-1207-5p were independent risk factors of LNM. MiR-1207-5p could serve as a useful biomarker in the prediction of LNM in gastric cancer.

Prognostic value and clinicopathological significance of programmed cell death ligand 1 (PD-L1) expression in resected gastric cancer: A meta-analysis.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e15512-e15512
Author(s):  
Shuixiu Yu ◽  
Jing Ning ◽  
Wei Ouyang ◽  
Lingzhi Ding ◽  
Kaisu Lin ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Distant Metastasis ◽  
Prognostic Value ◽  
Meta Analysis ◽  
High Expression ◽  
Node Metastasis ◽  
Clinicopathological Significance ◽  
Resected Gastric Cancer

e15512 Background: Programmed death ligand 1 (PD-L1) expression has become a promising biomarker in predicting the efficacy of immune checkpoint inhibitors in various advanced cancers, including gastric cancer (GC). However, the prognostic value and clinicopathological significance of PD-L1 in GC is still not clearly identified. Hence, we carried out a meta-analysis to investigate the potential role of PD-L1 in GC, expecting to provide new clues for the judgement of prognosis in resected gastric cancer. Methods: A literature search strategy was performed from the PubMed, Web of Science, EMBASE, and the Cochrane Library database as of December 1, 2018. Relevant data was rigorously extracted from the included literatures. Hazard ratios (HRs) and Odds ratios (ORs) along with 95% confidence intervals (95% CIs) were used to evaluate the prognostic value or clinicopathological significance of PD-L1 expression in GC. Results: A total of 21 studies containing 6021 patients fitted into our meta-analysis. The pooled HRs indicated that PD-L1 high-expression accompanied with a worse overall survival (OS) (HR=1.28, 95% CI: 1.01-1.62, P=0.04) in GC, while no correlation with disease-free survival (DFS) (HR=0.88, 95%CI: 0.53-1.45, P=0.61). Subgroup analysis showed that PD-L1 high-expression was negatively associated with distant metastasis groups (OR=0.66, 95%CI:0.48-0.89, P=0.01), but was positively related to elderly(OR=1.19, 95%CI: 1.01-1.40, P=0.04), lymph-node metastasis(OR=1.63, 95%CI: 1.08-2.46, P=0.02), deeper tumor infiltration(OR=1.73, 95%CI: 1.08-2.79, P=0.02), Epstein-Barr virus infection positive (EBV+) (OR=8.01, 95%CI: 3.10-20.72, P<0.0001), and MET positive (MET+) groups (OR=1.78, 95%CI: 1.05-3.00, P=0.03). Conclusions: Our meta-analysis found that the high-expression of PD-L1 accompanied with a poor OS. Moreover, PD-L1 high-expression was related to age, lymph-node metastasis, depth of infiltration, distant metastasis, EBV infection, and MET status.

scholarly journals Long non-coding RNA XIST expression as a prognostic factor in human cancers: A meta-analysis

2019 ◽  
Vol 34 (4) ◽  
pp. 327-333
Author(s):  
Shuai Yin ◽  
Jiayu Dou ◽  
Guifang Yang ◽  
Fangfang Chen
Keyword(s):  
Overall Survival ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Cancer Patients ◽  
Distant Metastasis ◽  
Poor Prognosis ◽  
Meta Analysis ◽  
High Expression ◽  
Xist Expression ◽  
Node Metastasis

A large number of literature has shown that high expression of X inactive-specific transcript (XIST) is associated with poor prognosis and metastasis of cancer in patients. However, most of this literature is limited by the small sample sizes and discrete outcomes. Therefore, a meta-analysis was performed to investigate the relation between XIST expression and tumor node metastasis (TNM) stage, lymph node metastasis, distant metastasis, and overall survival of cancer patients. We searched for literature in PubMed, Embase, and Web of Science. The pooled hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to evaluate the association of XIST expression with prognosis and clinicopathological characteristics of cancer patients. Finally, a total of 14 articles involving 1123 patients were included in this meta-analysis. The results suggested that high expression of XIST has a significant relationship with a relatively poor overall survival for patients with malignant tumors (HR 1.82; 95% CI 1.32, 2.52; P = 0.0003). Moreover, high expression of XIST was significantly associated with poor TNM stage (OR 3.64; 95% CI 2.62, 5.07; P < 0.0001), lymph node metastasis (OR 2.39; 95% CI 1.65, 3.46; P < 0.0001) and distant metastasis (OR 2.84; 95% CI 1.90, 4.23; P < 0.0001). In conclusion, high expression of lncRNA XIST may be a predictive factor of poor prognosis in human cancers.

scholarly journals Clinicopathological Significance of Neuropilin 1 Expression in Gastric Cancer: A Meta-Analysis

2020 ◽  
Vol 2020 ◽  
pp. 1-8
Author(s):  
Hui Cao ◽  
Yan Li ◽  
Limin Huang ◽  
Banjun Bai ◽  
Zhong Xu
Keyword(s):  
Gastric Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Tumor Size ◽  
Early Stage ◽  
Meta Analysis ◽  
Group Versus ◽  
Tnm Stage ◽  
Node Metastasis ◽  
Neuropilin 1

Background. Neuropilin 1 (NRP1) is involved in tumorigenesis, development, invasion, and metastasis by promoting angiogenesis of tumors. The study is aimed at evaluating the correlation between the expression of NRP1 protein and clinicopathological features of gastric cancer by meta-analysis. Methods. The published studies were searched in databases including CNKI, Wanfang, Chongqing VIP, Web of Science, and PubMed online. Clinical case studies were included to compare the correlation between NRP1 protein expression and clinicopathological characteristics of gastric cancer. The quality of the included literatures was evaluated by NOS scale. Meta-analysis was performed by Stata software to calculate the odds ratio (OR) and 95% confidence interval (CI). Results. A total of 12 studies were included in this analysis, involving 1,225 patients with gastric cancer. The analysis indicated that the expression of NRP1 protein in gastric cancer tissues was lower in the group of early stage versus advanced stage (OR=0.128, 95%CI=0.059−0.277, P≤0.001), tumor size less than 5 cm versus more than 5 cm (OR=0.443, 95%CI=0.310−0.632, P≤0.001), TNM stage I-II group versus stage III-IV patients (OR=0.736, 95%CI=0.589−0.919, P=0.007), well to medium differentiation group versus poor differentiation group (OR=0.735, 95%CI=0.632−0.854, P≤0.001), and nonlymph node metastasis group versus lymph node metastasis group (OR=0.667, 95%CI=0.522−0.854, P≤0.001). The expression of NRP1 protein in gastric cancer was not related to gender, age, and Laurèn’s classification. Conclusion. The expression of NRP1 protein in gastric cancer is closely correlated to clinical stage, tumor size, TNM stage, differentiation, and lymph node metastasis.

scholarly journals Lack of Relationship Between PROX1 Expression and Clinicopathological Parameters and Prognosis in Gastric Cancer Patients: A Meta-analysis and TCGA Analysis

2021 ◽  
Author(s):  
Zirui Jia ◽  
Yuhang Wang ◽  
Jiacheng Gao ◽  
Guo Zu
Keyword(s):  
Gastric Cancer ◽  
Overall Survival ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Tumor Size ◽  
Meta Analysis ◽  
Tnm Stage ◽  
Node Metastasis ◽  
Prox1 Expression ◽  
The Relationship

Abstract Background:The relationship between PROX1 expression and clinicopathological characteristics and prognosis in patients with gastric cancer (GC) is hotly contested and continues to be so. The aim of this study is to determine the clinicopathological and prognostic significance of PROX1 expression in patients with GC.Methods:PROX1 expression in GC patients was evaluated clinicopathologically and in terms of overall survival (OS) using a systematic literature search and meta-analysis. Additionally, the Cancer Genome Atlas (TCGA) and The Genotype-Tissue Expression (GTEx) datasets were utilized to examine the relationship between PROX1 expression and clinicopathological significance and overall survival (OS) in GC patients.Results:A total of 8 studies pooling 1289 GC patients were included in the assessment. PROX1 expression, in GC patients, was shown to be unrelated to gender (odds ratio (OR) : 1.234, 95%CI: 0.958-1.590, P = 0.104), depth of tumor invasion (OR: 0.742, 95%CI:0.428-1.287, P = 0.289), lymph node metastasis (OR: 2.161, 95%CI: 0.808-5.779, P = 0.125), TNM stage (OR: 1.324, 95%CI: 0.572-3.066, P = 0.513), tumor size (OR: 0.889, 95%CI: 0.502-1.576, P = 0.687), metastasis (OR: 1.096, 95%CI: 0.470-2.555, P= 0.763), 1-year OS (OR: 0.908, 95%CI: 0.631-1.306, P = 0.602), 3-years OS (OR: 1.234, 95%CI: 0.482-3.160, P = 0.661) and 5-years OS (OR: 0.853, 95%CI: 0.266-2.736, P = 0.790). Patients with high PROX1 expression had a worse OS than those with low PROX1 expression, according to TCGA analyses, however the difference was not statistically significant (p=0.119).Conclusion:The expression of PROX1 was shown to be unrelated to gender, TNM stage, depth of invasion, tumor size, stage, tumor cell metastasis, or lymph node metastasis. The expression of PROX1 was also unrelated to OS and it failed to be a meaningful biomarker to prevent and diagnose GC.

Sign in / Sign up

Export Citation Format

Share Document